The present invention relates to the use of Raman spectroscopy for the monitoring and assessment of viral titre and/or viral component abundance.

Increased levels of soluble urokinase-type plasminogen activator receptor (suPAR), particularly a plasma level of over 4.75 ng/ml or 6 ng/nl, have been found to be a predictor of whether a subject with COVID-19 symptoms and/or SARS-CoV-2 infection will require oxygen supplementation.

A composition is provided comprising a therapeutically active amount of vitamin K for administering to a subject as prophylactic for preventing or reducing the risk of developing severe disease or mortality by COVID-19 or a similar infectious disease, or as therapeutic for preventing said disease becoming more severe or reducing the severity of said disease. Also provided is a diagnostic test to estimate the risk of developing severe disease or mortality by COVID-19 or a similar infectious disease in a subject involving assessing vitamin K status in blood, serum or plasma of said subject.

The invention relates to a new non-invasive test making it possible to detect infection by the SARS-CoV-2 virus in a patient, using values of Apolipoprotein A1 alone or in combination with other markers.

Provided herein are methods of screening for agents that can partition in viral condensates and therefore may be effective anti-viral agents. Also disclosed are methods of optimizing the activity and reducing the side effects of known or suspected anti-viral agents by screening the portioning of modified known or suspected anti-viral agents in viral condensates and other condensates occurring in cells (e.g., transcriptional condensates).

The present invention addresses the problem of providing a means for detecting a constituting protein of nucleocapsid derived from SARS-CoV-2. This problem has been solved by providing an antibody binding to a constituting protein of nucleocapsid derived from SARS-CoV-2 or a fragment of the antibody, a method for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid with the use of the antibody or a fragment thereof, a kit for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid, said kit containing the antibody or a fragment thereof, etc.

Disclosed herein is a novel class of isolated binding molecules including monoclonal antibodies that targets a broadly conserved epitope within the marburgvirus species. Certain aspects provide an effective treatment option for hemorrhagic fever caused by marburgviruses.

The virus test device encompasses a pseudo-receptor film having pseudo-receptors mimicking a structure of a host-cell receptor, which binds specifically to a target virus, a virus introducing-tube for sucking down an air-under-test (AUT) containing the target viruses, to compress the AUT into a high-speed air-flow of aerosols-under-test, concentrating the target viruses contained in the AUT, and to eject the high-speed air-flow to the pseudo-receptor film, a signal conditioner for converting physical signals, which represent alterations of physical states of the pseudo-receptor film ascribable to specific bindings of the pseudo-receptors with the target viruses, to electric signals.

A viral exposure signature (VES) that can identify early stage, pre-symptomatic hepatocellular carcinoma (HCC) among at-risk patients is described. The VES was developed using serological profiling and synthetic virome technology to identify unique viral peptide epitopes corresponding to 61 viral species. Methods of identifying a subject with early stage (pre-symptomatic) HCC using the VES are described.

Provided are an anti-RS virus antibody with high sensitivity and a test reagent using the antibody.

An anti-RS virus N protein monoclonal antibody, comprising a heavy chain variable region consisting of the amino acid sequence as set forth in SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence as set forth in SEQ ID NO: 2, 3 or 4, or an antigen-binding fragment thereof.